ABSTRACT
One of the greatest advances in the care of patients with myocardial infarction (MI) has been recognition of the pivotal role of platelets in the pathophysiology of coronary thrombosis. Not only are platelets influential in thrombus propagation during acute coronary syndromes (ACS), but they are also key contributors to the enhanced thrombogenicity associated with the implantation of intracoronary stents. Consequently, platelets have become the primary targets for pharmacologic therapy in patients with cardiac ischemic syndromes.
